One of the most immediate ways we’ll experience the benefits of rescheduling cannabis is on medical and scientific research. Keeping cannabis in the Schedule I category imposed massive regulatory barriers that made it difficult to study the plant, even for renowned and established clinical or scientific researchers. Strict DEA requirements and severely limited supply of cannabis that could be studied, were all major hurdles for researchers.
A new collaboration brings together iconic functional glass, carefully selected cannabis genetics and a mission…
This interview by Micah Johnson originally appeared in High Times Local, produced under license by…
Congress's watchdog confirmed the DEA has no complete written procedures for drug scheduling. Learn why…
This column originally appeared in Cultivated, a cannabis industry newsletter. Subscribe here. You know the…
The DEA has opened a new registration process for state-licensed medical cannabis manufacturers, distributors and…
This November gathering will bring psychedelic education into conversation with music, visual art, comedy, philosophy,…